Heart failure patients experience exercise intolerance and functional limitation every day. While the targeting of functional capacity is an important unmet need, this study found that the change in peak oxygen uptake did not differ between patients taking omecamtiv mecarbil and placebo.

How do current guideline-directed medical therapies for heart failure impact exercise capacity? How does omecamtive mecarbil differ from other heart failure pharmacotherapies?

In this interview, Gregory Lewis, MD and Jeroen J. Bax PhD, MD, FACC, with Ioannis Mastoris, MD, MPHcand, discuss Late Breaker: METEORIC-HF: The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic HFrEF.

Related References:

1. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Lewis GD, Docherty KF, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Ponikowski P, Böhm M, Teerlink JR, Heitner SB, Kupfer S, Malik FI, Meng L, Felker GM. Circ Heart Fail. 2022 Mar 3:CIRCHEARTFAILURE121008970. doi: 10.1161/CIRCHEARTFAILURE.121.008970. Teerlink J, GALACTIC Trial, NEJM, 2021 LBCT: major study

Clinical Topics: Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Exercise

Keywords: ACCELLite, Heart Failure, Exercise

< Back to Listings